Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChong WeiYZYan ZhangWWWei Wang

Discussion

Loading...

Member takes

Overview

Clinical trial reveals golidocitinib's potential for improving anti-tumor activity in peripheral T-cell lymphoma, suggesting enhanced treatment effectiveness.

Key Points

  • To evaluate the anti-tumor activity and tolerability of golidocitinib in combination with CHOP for PTCL.
  • Ongoing phase 1/2 trial with a single-center, single-arm design.
  • Patients are treated with Go-CHOP: golidocitinib plus CHOP regimen.
  • Assessment includes phase 1 dose-escalation and phase 2 dose-expansion for safety and efficacy.
  • Eighteen patients enrolled, with an overall response rate of 80.0%.
  • Seventy-three percent achieved complete response at the end of Go-CHOP therapy.
  • Neutropenia was the most common treatment-related adverse event, observed in over 60% of patients.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d54fhttps://doi.org/10.1182/blood-2025-6322
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre2025
  2. 2Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  3. 3Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study2025 · 1 citations
  4. 4Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025
  5. 5Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)2026 · 2 citations